Incidence of lower respiratory tract infection and associated viruses in a birth cohort in the Philippines

Kanako Otani1, Mayuko Saito1, Michiko Okamoto1, Raita Tamaki2,3, Mariko Saito-Obata1, Taro Kamigaki1, Irene C. Lirio4, Edelwisa Segubre-Mercado4, Veronica Tallo4, So corro Lupisan4 and Hitoshi Oshitani1*

Abstract

Background: Lower respiratory tract infection (LRTI) is an important cause of morbidity and mortality in infants and young children. However, the etiological role of viruses and the timing of developing LRTI are not well defined.

Methods: We analyzed the data of a prospective cohort study in the Philippines as a birth cohort. We detected LRTI among children who visited healthcare facilities with respiratory symptom, and collected nasopharyngeal swabs for virus detection. We analyzed the incidence rates (IRs) and cumulative proportion of LRTI and severe LRTI by age group and each virus detected.

Results: A total of 350 LRTI episodes were observed from 473 child-years yielded from 419 children. The IRs of LRTI were 70.8, 70.7, and 80.8 per 100 child-years for 0–5, 6–11, and 12–23 months of age, respectively. By 12 months of age, 45% of children developed LRTI at least once. Rhinovirus and respiratory syncytial virus were the most frequently detected viruses in all age groups. However, the IRs of influenza virus were low especially at 0–5 months of age.

Conclusions: We identified various patterns of age-specific IRs of LRTI and severe LRTI for different viruses, which should be considered to establish more effective interventions including vaccinations.

Keywords: Lower respiratory tract infection, Birth cohort, Respiratory virus, Incidence, Philippines

Background

Lower respiratory tract infection (LRTI) is a leading cause of hospital admissions and mortality for children aged <5 years worldwide [1]. It is estimated that more than 650,000 children in this age group died due to LRTI in 2016, and most of them occurred in low- and middle-income countries (LMICs) [2]. Bacterial pathogens such as Streptococcus pneumoniae and Hemophilus influenzae type b (Hib) have been shown to be a major cause of LRTI deaths in children [3, 4]. However, more recent studies have identified that respiratory viruses such as respiratory syncytial virus (RSV) [5] and influenza virus (IFV) [6] have a significant global disease burden among children, including a mortality impact, especially in LMICs.

Almost all children experience at least one episode of RSV infection by age 2 years [7], and infants <3 months of age had the highest incidence of severe RSV infections [8]. In contrast, the incidence of severe IFV infections is higher in infants aged 6–11 months compared to those aged <6 months [9]. It is important to understand the age-specific incidence of severe illnesses associated with different viruses to develop more effective strategies for interventions, including vaccinations. Effective vaccines for IFV are available, and the World Health Organization (WHO) strongly recommends pregnant
women to be vaccinated to protect both the mothers and the infants [10]. There are still no available vaccines for RSV, but there are several promising vaccine candidates [11]. Both pregnant women and infants are considered to be a target group for RSV vaccination [12]. If infants aged < 6 months have a higher disease burden of RSV infections, maternal vaccination might be more important to minimize the impact of RSV. Although there are some available data on the incidences of virus-specific LRTI from birth cohort studies [8, 13], data are still not sufficient, especially in LMICs.

We have conducted a pediatric cohort study for children aged < 5 years in Biliran Island in the Philippines. We previously reported detailed incidence rates (IRs) and risk factors for RSV-associated LRTI (RSV-LRTI) using the cohort data [14]. In the present study, we analyzed the same cohort data as a birth cohort to identify the age-specific incidence of LRTI by different viruses. In addition to RSV, we also included IFV, adenovirus (AdV), rhinovirus (RV), enterovirus (EV), human metapneumovirus (MPV), and parainfluenza virus (PIV) in the analysis.

**Methods**

**Study population**

In the original cohort study, we followed children aged < 5 years who lived in two communities in Biliran Island from March 2014 to June 2016. Biliran Province consists of the main island (Biliran Island, 556 km²) and small islands with a total population of about 172,000 [15]. In Biliran Province, the main industry is agriculture and fishery, and socioeconomic status (SES) is generally low [16]. Pneumococcal-conjugate vaccines (PCV) and Hib conjugate vaccines were introduced in 2015 and 2013, respectively.

The study design of the original cohort study was described elsewhere [17, 18]. Briefly, children aged < 5 years were identified by a pre-study census that was conducted by visiting all households in the study areas. Pregnant women were identified at primary healthcare facilities or during the household visit, and newborn infants were also enrolled in the cohort throughout the study period. Demographic and socioeconomic information was obtained using a structured questionnaire at enrollment and the SES score was assessed as described elsewhere [19]. Study nurses visited each household every two weeks to check if cohort children had any respiratory symptoms and recommended the caregivers to take their children to healthcare facilities when children had difficulty breathing or chest indrawing.

In this study, we included only birth cohort children who were enrolled within 28 days after the birth in the analysis. They were followed up to 2 years of age or until the end of the original cohort study.

**Identification, classification, and case count of LRTI episodes**

We included children who visited primary healthcare facilities or the outpatient clinic of the Biliran Provincial Hospital (BPH) with cough, coryza, or difficulty breathing, and those admitted to the BPH due to severe pneumonia based on the criteria of the Integrated Management of Childhood Illness (IMCI) [20, 21]. The BPH is the sole hospital providing secondary healthcare in the island. The study nurses or physician conducted physical examinations, including checking the presence of chest indrawing and measuring the respiratory rate and percutaneous oxygen saturation (SpO₂) using a pulse oximeter (PalmSAT 2800; Nonin Medical Plymouth, MN). Illness history of cough, difficulty breathing, and danger signs (inability to feed, sleeping most of the time, or difficult to awake) were also obtained from the caregivers.

We defined and classified LRTI based on the definitions proposed by the WHO experts group [12] with some modifications. An episode of LRTI was defined when a child had cough or difficulty breathing and fast breathing (≥ 60 breaths per minute for children aged < 2 months, ≥ 50 breaths per minute for children aged 2–11 months, ≥ 40 breaths per minute for children aged 12–23 months) or SpO₂ < 95%. As children aged < 2 months were not included in the original definitions, the respiratory rate of ≥ 60 breaths per minute was used as fast breathing for this age group [22]. In the original definitions, severe LRTI and very severe LRTI were defined as LRTI with chest indrawing or SpO₂ < 93% and LRTI with SpO₂ < 90% or at least one of the danger signs (inability to feed, failure to respond, and unconsciousness), respectively. In this analysis, severe LRTI and very severe LRTI were combined as severe LRTI. Sleeping most of the time or difficult to awake was used to substitute failure to respond or unconsciousness in the original definitions. If an LRTI episode did not meet the severe LRTI definitions, it was classified as “non-severe LRTI.” If SpO₂ was measured after starting the oxygen treatment, the SpO₂ value was considered as < 95%. If the severity was not determined due to incomplete SpO₂ data, such a case was classified as “undefined LRTI.” Total LRTI included non-severe LRTI, severe LRTI, and undefined LRTI. An episode occurred after at least seven days without any respiratory symptoms was regarded as a new episode. If a child visited the healthcare facilities more than once during one episode, the most severe category of LRTI was used in the analysis.
Laboratory diagnosis for virus detection

Nasopharyngeal swabs (NPS) were collected from cohort children who visited healthcare facilities. Conventional polymerase chain reaction (PCR) was performed to detect AdV [23], RV [24], EV [24] and PIV (PIV-1, PIV-2, PIV-3 and PIV-4) [25], and real-time PCR was used to detect IFV (IFV-A, including A(H1N1)pdm and A(H3N2), and IFV-B) [26]. Multiplex Real-time PCR was performed to detect RSV [27, 28] and MPV [29]. Positive samples were further classified into species or subgroups using Sanger sequencing for RV (RV-A, RV-B and RV-C) [24] and EV (EV-A, EV-B, EV-C and EV-D) [24], and PCR for RSV (RSV-A and RSV-B) [30, 31]. The details of the procedure were described elsewhere [17]. When multiple NPS samples were collected for one LRTI episode, all detected viruses were included in the analysis. Even if the child visited multiple health facilities, the laboratory test results were integrated using unique identification code of the study.

Data analysis

Baseline characteristics were compared between age of follow-up using chi-square test. Incidence rates were calculated as the sum of episodes divided by the sum of the child-years observed in each age group. Poisson 95% confidential intervals (95% CIs) for IRs were computed. Incidence rate ratios (IRRs) were calculated by comparing the IRs between non-severe LRTI and severe LRTI and 95% CIs for IRRs were obtained using two-sided exact significance test. Cumulative proportions of children who developed LRTI were estimated using Kaplan–Meier survival analysis by the first and subsequent LRTI separately, and by detected viruses. When multiple viruses were detected in one LRTI episode, these LRTIs were included for each virus-specific survival curve. Stata version 15 (StataCorp, College Station, TX) was used for data analysis.

Ethics approval

Informed consent was obtained from the guardians of all participants at enrollment. The study protocol was approved by the Ethics Committee of Tohoku University Graduate School of Medicine, Japan, and the Institutional Review Board of the Research Institute for Tropical Medicine (RITM), Philippines. All methods were performed in accordance with the relevant guidelines and regulations.

Results

Characteristics of cohort children

A total of 419 children, after excluding four children who withdrew from the study before age 28 days, were included in the birth cohort analysis (Fig. 1), yielding 473 child-years of follow-up. The median age at enrollment was 14 days. In total, 183 children were followed until 1 year of age and 64 children were followed until 2 years of age, whereas 84 children were not followed until 6 months of age. The median follow-up age was 14.1 months (Interquartile range: 7.4–20.9). When we stratified the children according to their length of the follow-up, there was no significant difference in those characteristics among the groups except month of birth. The baseline characteristics of participants by age of follow-up are shown in Additional file 3: Table S1. More than half of the children were from households with low SES score (< 30 indicating extreme poverty). The coverage of the PCV and Hib conjugate vaccine was 18.6% (46/247) and 58.3% (144/247), respectively, among children who were followed at least until 1 year of age.

Classification of LRTI

Among 419 cohort children, 350 LRTI episodes were identified (Fig. 1). Of those, 13.1% (46/350) were classified as LRTI by the SpO2 value only. Of 350 episodes, 233 and 107 episodes were classified as non-severe LRTI and severe LRTI, respectively. For 10 LRTI episodes, the severity of LRTI was not classified (undefined LRTI).

Incidence rates of total LRTI and severe LRTI

The overall IRs of total LRTI and severe LRTI were 74.0 (CI 66.4–82.2) and 22.6 (CI 18.5–27.3) per 100 child-years, respectively (Table 1). There were no differences in IRs of total LRTI between age groups (0–5 months: 70.8 (CI 58.9–84.4), 6–11 months: 70.7 (CI 57.7–85.7) and 12–23 months: 80.8 (CI 67.2–96.5)). The IR of severe LRTI for 0–5 months of age (25.7 per 100 child-year) was higher than that at 6–11 months (24.7 per 100 child-year) and 12–23 months of age (17.1 per 100 child-year), although it was not statistically significant (p = 0.866 and p = 0.096, respectively). The IRR of severe LRTI compared with non-severe LRTI was 0.58 (CI 0.40–0.86), 0.57 (CI 0.37–0.87) and 0.28 (CI 0.17–0.44) for 0–5 months, 6–11 months and 12–23 months of age, respectively.

Cumulative proportion of children who developed LRTI

The cumulative proportion of children who developed at least one LRTI was 44.9% and 63.7% at 12 and 24 months of age, respectively (Fig. 2A). The level of increase in the proportion of the first LRTI decelerated after 9 months. By 24 months, 35.5% of children developed second LRTI. There were 21.6% of children who experienced three or more LRTIs by 24 months. The cumulative proportion of children who developed severe LRTI was 18.9% and
29.8% by 12 and 24 months, respectively (Fig. 2B). The proportion of children who developed second severe LRTI by 24 months was estimated at 8.8%.

**Distribution of viruses detected in children with LRTI**

Among 350 LRTI episodes, NPS samples were collected from 329 episodes (94.0%). Of those, at least one virus was detected from 228 episodes (69.3%). Among seven viruses, RV was the most frequently detected virus (87/329, 26.4%) followed by RSV (56/329, 17.0%) (Table 2), whereas IFV was detected in only 5.8% of LRTI episodes. When we compare the detection rates by severity of LRTIs, RSV was more frequently detected in severe LRTI (23/104, 22.1%) than in non-severe LRTI (30/216, 13.9%) and PIV was detected more in non-severe LRTI (22/216, 10.2%) than in severe LRTI (6/104, 5.8%). However, the differences did not reach the statistical significance (p = 0.064, p = 0.190, respectively). Two viruses were detected from 16 episodes, and co-detection of RSV and RV was most frequently observed (8/16, Additional file 4: Table S2). The epidemic curves of each virus in the original cohort study of children aged < 5 years are shown in Additional file 1: Figure S1.

**Cumulative proportion of children who developed virus-specific LRTI**

Figure 3 shows the cumulative proportion of virus-specific LRTI by severity. At the age of 24 months, the cumulative proportion of non-severe and severe LRTI was 21.4% and 8.6% for RV-associated LRTI (RV-LRTI). The gap between non-severe and severe RV-LRTI became wider after 3 months of age. On the other hand, the gap was not observed until 15 months of age for RSV-LRTI. The cumulative proportion of non-severe RSV-LRTI and
Table 1  Incidence rates of LRTIs per 100 child-years and IRRs for severe LRTI compared to non-severe LRTI in Biliran, Philippines, from March 2014 to June 2016

| LRTI classification | 0–5 months | 6–11 months | First year of life (0–11 months) | Second year of life (12–23 months) | Total |
|--------------------|------------|-------------|----------------------------------|------------------------------------|-------|
|                     | n          | IR [95% CI] | IRR [95% CI]                     | n                                  | IR [95% CI] | IRR [95% CI] | n                                  | IR [95% CI] | IRR [95% CI] | n                                  | IR [95% CI] | IRR [95% CI] |
| Non-severe          | 77         | 44.0        | [34.7–54.9]                      | 63                                 | 43.2       | [33.2–55.3]  | 140                                | 43.6       | [36.7–51.5]  | 93                                 | 61.1       | [49.3–74.9]  |
| Severe              | 45         | 25.7        | [18.7–34.4]                      | 36                                 | 24.7       | [17.3–34.2]  | 81                                 | 25.2       | [20.0–31.4]  | 26                                 | 17.1       | [11.2–25.0]  |
| Undefined           | 2          | –           | –                                 | 4                                  | –          | –           | 6                                  | –          | –          | 4                                  | –          | –          |
| Total               | 124        | 70.8        | [58.9–84.4]                      | 103                                | 70.7       | [57.7–85.7]  | 227                                | 70.7       | [61.8–80.6]  | 123                                | 80.8       | [67.2–96.5]  | 350                                | 74.0       | [66.4–82.2]  |

Total LRTI included non-severe LRTI, severe LRTI and undefined LRTI. Observed child-years were 175.2, 145.7, and 152.2 at age 0–5, 6–11, and 12–23 months, respectively.
LRTI, lower respiratory tract infection; IR, incidence rate; IRR, incidence rate ratio; 95% CI, 95% confidence interval.
Fig. 2  Cumulative proportion of children who developed first and subsequent LRTI. A Survival curves show cumulative proportions (%) of children who developed the first through fifth total LRTI episodes, including “non-severe LRTI,” “severe LRTI” and “undefined LRTI.” Although four children developed LRTI six times, the sixth episode is not shown in the figure. B Curves show the cumulative proportion (%) of children who developed “severe LRTI.” Although two children developed severe LRTI four times and one developed it five times, the fourth and fifth episodes are not shown in the figure. Percentages (shown in brackets) show the cumulative proportion at 24 months of age. Abbreviation: LRTI, lower respiratory tract infection

Table 2  Detected viruses and subtypes or species from cases with LRTI in Biliran, Philippines, from March 2014 to June 2016

| Detected virus | Non-severe LRTI | Severe LRTI | Undefined LRTI | Total |
|---------------|-----------------|-------------|----------------|-------|
| AdV           | 3 (1.4%)        | 0 (0.0%)    | 0 (0.0%)       | 3 (0.9%) |
| RV            | 59 (27.3%)      | 26 (25.0%)  | 2 (22.2%)      | 87 (26.4%) |
| RV-A          | 33              | 13          | 2              | 48    |
| RV-B          | 5               | 0           | 0              | 5     |
| RV-C          | 21              | 13          | 0              | 34    |
| EV            | 6 (2.8%)        | 4 (3.9%)    | 0 (0.0%)       | 10 (3.0%) |
| EV-A          | 1               | 0           | 0              | 1     |
| EV-B          | 3               | 1           | 0              | 4     |
| EV-C          | 1               | 0           | 0              | 1     |
| EV-D (068)    | 1               | 3           | 0              | 4     |
| RSV           | 30 (13.9%)      | 23 (22.1%)  | 3 (33.3%)      | 56 (17.0%) |
| RSV-A         | 3               | 9           | 1              | 13    |
| RSV-B         | 27              | 12          | 2              | 41    |
| RSV-untyped   | 0               | 2           | 0              | 2     |
| MPV           | 6 (2.8%)        | 3 (2.9%)    | 0 (0.0%)       | 9 (2.7%) |
| PIV           | 22 (10.2%)      | 6 (5.8%)    | 0 (0.0%)       | 28 (8.5%) |
| PIV-1         | 3               | 3           | 0              | 6     |
| PIV-2         | 1               | 0           | 0              | 1     |
| PIV-3         | 17              | 3           | 0              | 20    |
| PIV-4         | 1               | 0           | 0              | 1     |
| IFV           | 11 (5.1%)       | 7 (6.7%)    | 1 (11.1%)      | 19 (5.8%) |
| IFV-A         | 10              | 6           | 1              | 17    |
| IFV-B         | 1               | 1           | 0              | 2     |
| Co-detection  | 11 (5.1%)       | 4 (3.9%)    | 1 (11.1%)      | 16 (4.9%) |
| Negative      | 68 (31.5%)      | 31 (29.8%)  | 2 (22.2%)      | 101 (30.7%) |
| Sub-total     | 216 (100.0%)    | 104 (100.0%)| 9 (100.0%)     | 329 (100.0%) |
| Not tested    | 17              | 3           | 9              | 21    |
| Total         | 233             | 107         | 10             | 350   |

LRTI, lower respiratory tract infection; AdV, Adenovirus; RV, Rhinovirus; EV, Enterovirus; RSV, Respiratory syncytial virus; MPV, Human metapneumovirus; PIV, Parainfluenza virus; IFV, Influenza virus
severe RSV-LRTI at 24 month of age was 13.4% and 8.5%, respectively.

The cumulative proportion of RV-LRTI and RSV-LRTI increased from <1 month of age (Additional file 2: Figure S2, Fig. 3B and D). In contrast, the proportion of MPV-associated LRTI (MPV-LRTI) and IFV-associated LRTI (IFV-LRTI) did not increase until the first 3 months of age (Additional file 2: Figure S2, Fig. 3E and G).

Incidence of virus-specific LRTI by age group
When the IRs of the virus-specific LRTIs were stratified by age group, the IRs of RV- and RSV-LRTIs for 0–5 months of age were higher than those for 6–11 and 12–23 months (Table 3). In contrast, the IRs of EV-associated (EV-), MPV-, PIV-associated (PIV-) and IFV-LRTIs were higher in the older age group. However, these differences were not statistically significant (all \( p \geq 0.05 \)). When the virus-specific LRTIs were stratified by age group and severity, the IRR of severe RSV-LRTI to non-severe RSV-LRTI was higher for 6–11 months of age (IRR: 2.33, CI 0.53–13.98) than for 0–5 months (IRR: 0.73, CI 0.30–1.71) and 12–23 months of age (IRR: 0.42, CI 0.11–1.27) without statistical significance (Table 3).

Discussion
To our knowledge, this is the first study that applied the definition of LRTI with \( \text{SpO}_2 \) measurement by the WHO Working Group [12] for major respiratory viruses. Our data demonstrated the high IR of LRTI for children aged 1–2 years in rural areas of the Philippines (74.0 per 100 child-years). For children aged <1 year, the IR of LRTI (70.7 per 100 child-years) was higher than that of the study in South Africa (51 per 100 child-years) [32]. Although most of the other studies used the definitions of pneumonia of the IMCI [32–34] to define LRTI, we used the definitions proposed by the WHO Working Group [12], which include the \( \text{SpO}_2 \) value to define LRTI. This can be a reason for the high IRs of LRTI. However, only 13% of LRTI episodes in our study were defined by the \( \text{SpO}_2 \) value. Other factors such as low vaccine coverage for PCV and Hib conjugate vaccine in our study population may also have contributed to the high IRs. However, we did not test blood or respiratory samples for bacterial pathogens. Blood extraction was not feasible in our study setting because most of the episodes were identified in outpatient setting and the bacteremia was rare even in the hospitalized children with severe pneumonia in our previous study [20]. In addition, etiological significance is limited in children with pneumonia [35, 36]. Even higher IR of LRTI in the first year of life was reported from other cohort studies in Bangladesh (88.3 and 76.0 per 100 child-years for 0–5 and 6–11 months of age, respectively) [34] and India (96.0 per 100 child-years for 0–11 months of age) [33]. The incidence of LRTI may vary even within the country. The national statistics of the Philippines showed that Eastern Visayas Region to which Biliran Province belongs had a much higher incidence of acute LRTI and pneumonia than the national average [37]. Since our study was conducted in two rural communities in a small island, the results may not be applicable for the whole Philippines. However, our previous study confirmed similar patterns of viral etiology in four hospitals in different regions of the Philippines including...
Table 3. Incidence rates of virus-specific LRTIs per 100 child-years and IRRs for severe LRTI compared to non-severe LRTI in Biliran, Philippines, from March 2014 to June 2016.

| Detected virus | LRTI classification | 0–5 months | 6–11 months | 12–23 months |
|----------------|---------------------|------------|-------------|-------------|
|                | n | IR [95%CI] | IRR [95%CI] | n | IR [95%CI] | IRR [95%CI] | n | IR [95%CI] | IRR [95%CI] |
| AdV            | Non-severe | 0 | 0.0 [0.0–2.1] | 1 | 2 | 1.4 [0.2–5.0] | 1 | 1 | 0.7 [0.0–3.7] | 1 |
|                | Severe | 0 | 0.0 [0.0–2.1] | 0.00 [0.0–0.00] | 0 | 0.0 [0.0–25] | 0.00 [0.00–5.32] | 0 | 0.0 [0.0–24] | 0.00 [0.00–39.00] |
| Total          | 0 | 0.0 [0.0–2.1] | – | 2 | 1.4 [0.2–5.0] | – | 1 | 0.7 [0.0–3.7] | – |
| RV             | Non-severe | 24 | 13.7 [8.8–20.4] | 1 | 13 | 8.9 [48.1–15.3] | 1 | 22 | 14.5 [19.1–21.9] | 1 |
|                | Severe | 15 | 8.6 [48.1–14.1] | 0.63 [0.30–1.24] | 7 | 4.8 [19.9–99] | 0.54 [0.18–1.45] | 4 | 2.6 [0.7–3.7] | 0.18 [0.05–0.45] |
| Total          | 39 | 22.3 [15.8–30.4] | – | 21 | 14.4 [58.9–22.0] | – | 27 | 17.7 [11.7–25.8] | – |
| EV             | Non-severe | 1 | 0.6 [0.1–4.1] | 2.00 [0.10–17.99] | 1 | 0.7 [0.0–2.5] | 0.5 [0.01–0.96] | 1 | 0.7 [0.0–3.7] | 0.33 [0.01–4.15] |
|                | Severe | 3 | 1.7 [0.4–5.0] | – | 3 | 2.1 [0.4–6.0] | − | 4 | 2.6 [0.7–6.7] | – |
| Total          | 4 | 1.7 [0.4–5.0] | – | 6 | 2.1 [0.4–6.0] | – | 6 | 3.9 [15.8–8.6] | – |
| RSV            | Non-severe | 15 | 8.6 [48.1–14.1] | 1 | 3 | 2.1 [0.4–6.0] | – | 12 | 7.9 [41.1–13.8] | 1 |
|                | Severe | 11 | 6.3 [3.1–11.2] | 0.73 [0.30–1.71] | 7 | 4.8 [19.9–99] | 2.33 [0.53–13.98] | 5 | 3.3 [11.7–7.7] | 0.42 [0.11–1.27] |
| Total          | 27 | 15.4 [10.2–22.4] | – | 11 | 7.6 [38.13] | – | 18 | 11.8 [70.18] | – |
| MPV            | Non-severe | 1 | 0.6 [0.1–4.1] | – | 1 | 0.7 [0.0–3.8] | – | 4 | 2.6 [0.7–6.7] | 1 |
|                | Severe | 1 | 0.6 [0.1–4.1] | 1.00 [0.01–78.50] | 0 | 0.0 [0.0–25] | 0.00 [0.00–39.00] | 2 | 1.3 [0.2–4.7] | 0.50 [0.05–3.49] |
| Total          | 2 | 1.1 [0.1–4.1] | – | 1 | 0.7 [0.0–3.8] | – | 6 | 3.9 [15.8–8.6] | – |
| PIV            | Non-severe | 4 | 2.3 [0.6–5.8] | – | 7 | 4.8 [19.9–99] | 1 | 11 | 7.2 [3.6–12.9] | 1 |
|                | Severe | 2 | 1.1 [0.1–4.1] | 0.50 [0.05–3.49] | 4 | 2.7 [0.7–7.0] | 0.57 [0.12–2.25] | 0 | 0.0 [0.0–24.0] | 0.00 [0.00–0.40] |
| Total          | 6 | 3.4 [1.37] | – | 11 | 7.6 [38.13] | – | 11 | 7.2 [3.6–12.9] | – |
| IFV            | Non-severe | 3 | 1.7 [0.4–5.0] | 1 | 4 | 2.7 [0.7–7.0] | 1 | 4 | 2.6 [0.7–6.7] | 1 |
|                | Severe | 1 | 0.6 [0.1–4.1] | 0.33 [0.01–4.15] | 3 | 2.1 [0.4–6.0] | 0.75 [0.11–4.43] | 3 | 2.0 [0.4–5.8] | 0.75 [0.11–4.43] |
| Total          | 5 | 2.9 [0.9–6.7] | – | 7 | 4.8 [19.9–99] | – | 7 | 4.6 [19.9–95] | – |
| Co-detection   | Non-severe | 7 | 4.0 [1.6–8.2] | 1 | 3 | 2.1 [0.4–6.0] | – | 1 | 0.7 [0.0–3.7] | 1 |
|                | Severe | 2 | 1.1 [0.1–4.1] | 0.29 [0.03–1.50] | 1 | 0.7 [0.0–3.8] | 0.33 [0.01–4.15] | 1 | 0.7 [0.0–3.7] | 1.00 [0.01–78.50] |
| Total          | 9 | 5.1 [2.4–9.8] | – | 4 | 2.7 [0.8–7.0] | – | 3 | 2.0 [0.4–5.8] | – |
| Negative       | Non-severe | 20 | 11.4 [70.176] | 1 | 20 | 13.7 [84.21] | 1 | 28 | 18.4 [12.2–26.6] | 1 |
|                | Severe | 11 | 6.3 [3.1–11.2] | 0.55 [0.24–1.20] | 13 | 8.9 [48.153] | 0.65 [0.30–1.37] | 7 | 4.6 [18.9–9.5] | 0.25 [0.09–0.59] |
| Total          | 31 | 17.7 [12.0–25.1] | – | 34 | 23.3 [162.32] | – | 36 | 23.7 [166.32] | – |
| Total          | 75 | 42.8 [33.7–53.7] | 1 | 55 | 37.8 [284.4–3491] | 1 | 86 | 56.5 [45.2–69.8] | 1 |

Total LTRTI included non-severe LRTI, severe LRTI and undefined LRTI. Observed child-years were 175.2, 145.7, and 152.2 at age 0–5, 6–11, and 12–23 months, respectively. Episodes in which samples were not tested for virus detection were excluded (n = 21).

IR, incidence rate; IRR, incidence rate ratio; LRTI, lower respiratory tract infection; 95% CI, 95% confidence interval; AdV, Adenovirus; RV, Rhinovirus; EV, Enterovirus; RSV, Respiratory syncytial virus; MPV, Human metapneumovirus; PIV, Parainfluenza virus; IFV, Influenza virus.
difference might be due to different incidences of causative agents. In general, IFV and PIV are more commonly identified from older children compared with RSV and RV [46]. The study in India that showed higher incidence of LRTI for 12–23 months of age had high positivity rates for IFV and PIV [38], whereas most of other studies including our study, had high positivity rates for RSV and RV.

At least one virus was detected in 69.3% of LRTI episodes, which indicate the importance of respiratory viruses in LRTI for children aged <2 years. The most commonly identified virus was RV (26.4%) followed by RSV (17.0%). RSV has been recognized as the most important viral pathogens associated with hospitalized LRTI cases in infants and young children [5]. In our data, the highest IRs of RSV-LRTI and severe RSV-LRTI were observed in infants aged 0–5 months. A high IR of RSV associated pneumonia in this age group was reported from birth cohort study in Mali [40]. This age group is considered to be a prime target for RSV interventions including future RSV vaccinations [12]. However, we also observed a relatively high IR of RSV-LRTI in children aged 12–23 months, which is similar to our previous analysis of the same data set [14] and other studies [41, 42]. Although the IR of RSV-LRTI for 6–11 months of age was lower than those for 0–5 and 12–23 months of age, the IR of severe RSV-LRTI in this age group was higher than in 12–23 months, andIRR for severe LRTI compared to non-severe LRTI was even higher than that for 0–5 months of age. The same pattern was observed in the birth cohort study in Kenya [41]. When establishing the RSV vaccination strategy, it may be necessary to reduce the impact in older infants and young children.

In the present study, RV showed the highest IRs among detected viruses in all age groups. For 0–5 months of age, the IR of severe RV-LRTI was particularly high and incidence of RV-LRTI and severe RV-LRTI increased immediately after birth. However, the etiological importance of RV for LRTI in infants and young children is still controversial. A birth cohort study in Australia, which included healthy controls, showed that RV is more important than RSV as a cause of LRTI in infants <1 year of age [43]. On the other hand, another birth cohort study in South Africa indicated that RV had limited attribution to LRTI [44]. A meta-analysis also showed a low attributable fraction of RV [45]. Other studies also showed that many of RV infections were mild or asymptomatic, although RV was the most commonly detected virus [46, 47]. Analysis of attributable fraction by comparing RV positive rates between symptomatic cases and healthy control may underestimate a real impact of RV since virus shedding period after symptomatic RV infections may be longer [48]. Further studies are necessary to define an exact impact of RV in infants and young children.

The overall positivity rates of other viruses, including AdV, EV, MPV, PIV, and IFV were low ranging from 0.9% (AdV) to 8.5% (PIV). It has been shown that seasonal IFV has high disease burden particularly in infants aged <1 year [49]. Therefore, the WHO strongly recommends maternal IFV vaccination to protect both pregnant women and infants [50]. However, in our data, IFV was detected only in 5.8% of LRTI episodes and the IRs of IFV-LRTI were relatively low in all age groups, especially in infants aged <6 months (2.9 per 100 child-years), with only one severe IFV-LRTI in this age group. Other cohort studies also indicated lower IRs of IFV among infants compare to those of RV and RSV [34, 43, 44]. Further studies are necessary to define the disease burden of seasonal IFV in infants and the effectiveness of maternal vaccination. The detection rate of PIV (8.5%) in LRTI episodes was higher than IFV (5.8%). This was mainly due to a relatively large outbreak of PIV-3 during the study period. Incidences of other viruses including AdV, EV, and MPV were low. Although AdV, especially AdV type 7 [51], and EV, especially EV-D68 [52] were shown to be associated with severe LRTI with some fatal episodes in our hospital-based studies in the Philippines, the present study suggested a relatively small contribution of these viruses to overall LRTI in the study population.

The study has some limitations. First, we conducted the study for only 2 years and 3 months by recruiting newborns throughout the study period. Therefore, the observed period for each age group varied (Additional file 1: Figure S1). For example, the observation period for 12–23 months only covered 2015 and 2016. As viruses detected in the study had some seasonality and annual
fluctuation, the age and virus-specific IRs are affected by various observation periods among age groups. Second, we detected episodes with LRTI only at healthcare facilities. However, more than 90% of children in the study area sought care at healthcare facilities when they had pneumonia-like episode [16]. We believe that a majority of LRTI episodes were detected in the present study. Third, there was some delay in the recruitment of newborn babies for the study (median 14 days). We probably have missed some LRTI episodes that occurred before recruitment.

In conclusion, we identified various patterns of age-specific IRs of LRTI and severe LRTI for different viruses, which should be considered to establish more effective interventions including vaccinations.

**Abbreviations**

LRTI: Lower respiratory tract infection; AdV: Adenovirus; RV: Rhinovirus; EV: Enterovirus; RSV: Respiratory syncytial virus; MPV: Human metapneumovirus; PIV: Parainfluenza virus; IFV: Influenza virus; IRs: Incidence rates; IRRs: Incidence rate ratios; 95%CI: 95% Confidence intervals; SpO2: Percutaneous oxygen saturation; Hib: Hemophilus influenzae Type b; WHO: World Health Organization; SES: Socioeconomic status; PCV: Pneumococcal-conjugate vaccines; IMCI: Integrated Management of Childhood Illness; NPS: Nasopharyngeal swabs.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12879-022-07289-3.

**Additional file 1:** Figure S1. Number of LRTI episodes and number of children (mean) stratified by age group in the birth cohort, and number of virus positive samples observed in the original cohort study (among children aged <5 years) in Biliran, Philippines, from March 2014 to June 2016.

**Additional file 2:** Figure S2. Cumulative proportion of children who developed non-severe and severe virus-specific LRTI.

**Additional file 3:** Table S1. Characteristics of children in the birth cohort study by age at the end of follow-up in Biliran, Philippines, from March 2014 to June 2016.

**Additional file 4:** Table S2. Details of the detected viruses among cases with LRTI in which two viruses were detected in Biliran, Philippines, from March 2014 to June 2016.

**Acknowledgements**

We thank Dr. Balasbas C, Dr. Plaza D, and the medical staff in the RHU of Kawayan and Caibiran, BPH, and Biliran Provincial Health Office. We would like to also thank the research staff of the Tohoku-RITM Collaborating Research Center on Emerging and Re-emerging Infectious Diseases in Biliran and RITM, Dr. Emiko Nakagawa, Mrs. April Rose Ecalla Caparro-Rubi, and all the participants for support.

**Authors' contributions**

KO, MS, RT, VT, SL and HO conceived and designed the study. MO and MSO established viral detection methods, and MO, ICL and ESM performed the test. KO, MS, RT, MSO, TK, VT, SL and HO coordinated to obtain the data. KO, MS and HO analyzed the data. KO and MS drafted the manuscript with the assistance of MO and HO. All authors read and approved the final manuscript.

**Funding**

This work was funded by the Science and Technology Research Partnership for Sustainable Development (Grant Number JP16jm0110001, JP20wm0125001) from the Japan International Cooperation Agency and the Japan Agency for Medical Research and Development (AMED), the Japan Initiative for Global Research Network on Infectious Diseases (Grant Number JP16fm0108015) from the Ministry of Education, Culture, Sport, Science & Technology in Japan and the AMED, KAKENHI (Grant Number: JP16H052642, JP19K01072) from the Japan Society for the Promotion of Science, and Tohoku University Global Hagi Scholarship for Doctoral Students.

**Availability of data and materials**

The datasets generated and analysed during the current study are not publicly available due to ongoing research and analysis, but are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

Informed consent was obtained from the guardians of all participants at enrollment. The study protocol was approved by the Ethics Committee of Tohoku University Graduate School of Medicine, Japan, (Approved Number 2018-1-69 and 2018-1-70) and the Institutional Review Board of the Research Institute for Tropical Medicine (RITM), Philippines.

**Consent for publication**

Not applicable.

**Competing interests**

There was no conflict of interest between the authors.

**Author details**

1. Department of Virology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan. 2. Japan International Cooperation Agency, Tokyo, Japan. 3. Department of Disease Surveillance and Epidemic Response, Ministry of Health, Nairobi, Kenya. 4. Research Institute for Tropical Medicine, Metro Manila, Philippines.

**Received:** 30 November 2021 **Accepted:** 10 March 2022

**Published online:** 30 March 2022

**References**

1. Naghavi M, Abajobir AA, Abbafati C, et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1151–210.

2. Troeger C, Blacker B, Khalil IA, et al. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018;18(11):1191–210.

3. O’Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374(9693):893–902.

4. Wahl B, O’Brien KL, Greenbaum A, et al. Burden of Streptococcus pneumoniae and Hemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15. Lancet Glob Heal. 2018;6(7):e744–57.

5. Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modeling study. Lancet. 2017;390(10098):946–58.

6. Nair H, Brooks WA, Katz M, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet. 2011;378(9780):1917–30.

7. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986;140(6):543–6.

8. Kubale J, Kuan G, Gresh L, et al. Assessing the incidence of symptomatic respiratory syncytial virus illness within a prospective birth cohort in Managua, Nicaragua. Clin Infect Dis. 2020;20(10):2029–35.

9. Glezen WP, Taber LH, Frank AL, Gruber WC, Piedra PA. Influenza virus infections in children. Semin Pediatr Infect Dis. 1997;16(1):1065–8.
10. World Health Organization. Vaccines against influenza WHO position paper—November 2012. Wkly Epidemiol Rec. 2012;47(87):461–76.

11. Mazur NI, Higgins D, Nunes MC, et al. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis. 2018;18(10):e295–311.

12. Modjarra J, Giersing B, Kaslow DC, Smith PG, Moorthy VS. WHO consultation on Respiratory Syncytial Virus Vaccine Development Report from a World Health Organization Meeting held on 23–24 March 2015. Vaccine. 2016;34(2):190–7.

13. Nokes DJ, Okiro EA, Ngagea M, et al. Respiratory syncytial virus epidemiology in a birth cohort from Kilifi District, Kenya: infection during the first year of life. J Infect Dis. 2004;190(10):1828–32.

14. Ueno F, Tamaki R, Saito M, et al. Age-specific incidence rates and risk factors for respiratory syncytial virus-associated lower respiratory tract illness in cohort children under 5 years old in the Philippines. Influenza Other Respi Viruses. 2019;13(4):339–53.

15. Philippine Statistics Authority. Population of Region VIII—Central Visayas (Based on the 2015 Census of Population); 2016. https://psa.gov.ph/content/population-region-viii-central-visitas-based-2015-census-population. Accessed 12 Sep 2019.

16. Kosai H, Tamaki R, Saito M, et al. Incidence and risk factors of childhood pneumonia-like episodes in Biliran Island, Philippines—a community-based study. PLoS One. 2015;10(5):e0125909.

17. Furuse Y, Tamaki R, Okamoto M, et al. Association between preceding viral infection and subsequent respiratory illnesses among children: a prospective cohort study in the Philippines. J Infect Dis. 2019;219(2):197–205.

18. Tamaki R, Tallo VL, Tan AC, et al. Comprehensive entiopathological and epidemiological study on acute respiratory infections in children: providing evidence for the prevention and control of childhood pneumonia in the Philippines. J Disast Res. 2018;13(4):740–50.

19. Scheirer M. A Simple Poverty Scorecard for the Philippines. Philipp. J. Dev. 2007. http://dirp4.pids.gov.ph/ris/pjd/psdpjd07-2poverty.pdf. Accessed 12 Sep 2019.

20. Dembelle BP, Kamigaki T, Dapat C, et al. Aetiology and risk factors associated with the fatal outcomes of childhood pneumonia among hospitalised children in the Philippines from 2008 to 2016 a case series study BMJ Open. 2019;9(3):e026895.

21. World Health Organization. HANDBOOK. Integrated management of childhood illness; 2005. https://apps.who.int/iris/handle/10665/429399. Accessed 12 Sep 2019.

22. World Health Organization. Technical bases for the WHO recommendations on the management of pneumonia in children at first-level health facilities; 1991. https://www.who.int/maternal_child_adolescent/documents/ari_91_20/en/. Accessed 12 Sep 2019.

23. Hein A, Ebnet C, Harste G, Pring-Åkerblom P. Rapid and quantitative detection of human adenovirus DNA by real-time PCR. J Med Virol. 2003;70(2):228–39.

24. Suzuki A, Lupisan S, Furuse Y, et al. Respiratory viruses from hospitalized children with severe pneumonia in the Philippines. BMC Infect Dis. 2012. https://doi.org/10.1186/1471-2334-12-267.

25. Bellau-Pujol S, Valbert A, Legrand L, et al. Development of three multiplex RT-PCR assays for the detection of 12 respiratory RNA viruses. J Virol Methods. 2005;126:53–63.

26. National Institute for Infectious Diseases. Influenza Diagnosis Manual (Japanese); 2014. https://www.niid.go.jp/niid/images/lab-manual/Influenza2014.pdf. Accessed 12 Sep 2019.

27. Malasa R, Okamoto M, Chaimongkol N, et al. Molecular characterization of human respiratory syncytial virus in the Philippines, 2012–2013. PLoS One. 2015;10(11)e0142192.

28. Bonny C, Vankeerberghen A, Boel A, De Beenhouwer H. Use of a multiplex real-time PCR to study the incidence of human metapneumovirus and human respiratory syncytial virus infections during two winter seasons in a Belgian paediatric hospital. Clin Microbiol Infect. 2007;13(5):504–9.

29. Matsuzaki Y, Takashita E, Okamoto M, et al. Evaluation of a new rapid antigen test using immunochromatography for detection of human metapneumovirus in comparison with real-time PCR assay. J Clin Microbiol. 2009;47(9):2981–4.

30. Sato M, Saito R, Sakai T, et al. Molecular epidemiology of respiratory syncytial virus infections among children with acute respiratory symptoms in a community over three seasons. J Clin Microbiol. 2005;43(1):36–40.

31. Peret TCT, Hall CB, Schnabel KC, Goleb JA, Anderson LJ. Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community. J Gen Virol. 1998;79(9):2221–9.

32. Le Roux DM, Nicol MP, Myler L, et al. Lower respiratory tract infections in children in a well-vaccinated south African birth cohort: spectrum of disease and risk factors. Clin Infect Dis. 2019;69(9):1588–96.

33. Krishnan A, Kumar R, Broor S, et al. Epidemiology of viral acute lower respiratory infections in a community-based cohort of rural north Indian children. J Glob Health. 2019;9(1):010433.

34. Havers FP, Fry AM, Gossow J, et al. Population-based incidence of childhood pneumonia associated with viral infections in Bangladesh. Pediatr Infect Dis J. 2019;38(4):344–50.

35. Abdullahi O, Nyiro J, Lewa P, et al. The descriptive epidemiology of Streptococcus pneumoniae and Haemophilus influenzae nasopharyngeal carriage in children and adults in Kilifi district, Kenya. Pediatr Infect Dis J. 2008;27:59–64.

36. Spuesens EB, Fraaij PLA, Visser EG, et al. Carriage of Mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study. PLoS Med. 2015;12:e1001444.

37. Epidemiology Bureau Department of Health. The 2016 Philippine Health Statistics, 2019; https://www.doh.gov.ph/sites/default/files/publications/2016_PHILIPPINE-HEALTH-STATISTICS.pdf. Accessed 12 Sep 2019.

38. Broor S, Parveen S, Bharaj P, et al. A prospective three-year cohort study of the epidemiology and virology of acute respiratory infections of children in rural India. PLoS One. 2007;2:e491.

39. Sarna M, Ware RS, Sloots TP, Nissen MD, Grimwood K, Lambert SB. The burden of community-managed acute respiratory infections in the first 2-5 years of life. Pediatr Pulmonol. 2016;51(12):1336–46.

40. Buchwald AG, Tamboura B, Tennant SM, et al. Epidemiology, risk factors, and outcomes of respiratory syncytial virus infections in newborns in Bamako, Mali. Clin Infect Dis. 2019;68(11):1596–66.

41. Nokes DJ, Okiro EA, Ngagea M, et al. Respiratory syncytial virus infection and disease in infants and young children studied from birth in Kilifi District, Kenya. Clin Infect Dis. 2008;46:50–7.

42. Simões EAF, Mutyara K, Soh S, Agustian D, Hibberd ML, Kartasasmita CB. The epidemiology of respiratory syncytial virus lower respiratory tract infections in children less than 5 years of age in Indonesia. Pediatr Infect Dis J. 2011;30(9):778–84.

43. Kusel MMH, de Klerk NH, Holt PG, Kebadze T, Johnston SL, Sly PD. Role of respiratory viruses in acute upper and lower respiratory tract illness in the first year of life. Pediatr Infect Dis J. 2006;25(8):680–6.

44. Zar HJ, Barnett W, Stadler A, Gardner-Lubbe S, Myler L, Nicol MP. Aetiology of childhood pneumonia in a well vaccinated South African birth cohort: a nested case-control study of the Drakenstein Child Health Study. Lancet Respir Med. 2016;4(6):463–72.

45. Shi T, McLean K, Campbell H, Nair H. Aetiological role of common respiratory viruses in acute lower respiratory infections in children under five years: a systematic review and meta-analysis. J Glob Health. 2015;5(1):10408.

46. Boonyaratamakanitch J, Englund JA, Magaret AS, et al. Primary and repeated respiratory viral infections among infants in rural Nepal. J Pediatric Infect Dis Soc. 2020;9(1):21–9.

47. Sarna M, Ware RS, Lambert SB, Sloots TP, Nissen MD, Grimwood K. Timing of first respiratory virus detections in infants: a community-based birth cohort study. J Infect Dis. 2018;217(3):418–27.

48. Jurtti T, Lehtinen P, Vuorinen T, et al. Persistence of rhinovirus and enterovirus RNA after acute respiratory illness in children. J Med Virol. 2004;74(6):695–9.

49. Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med. 2003;342(4):232–9.

50. Madhi SA, Cutland CL, Kuwanda L, et al. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med. 2014;371(10):918–31.

51. Yamamoto D, Okamoto M, Lupisan S, et al. Impact of human adenovirus serotype 7 in hospitalized children with severe fatal pneumonia in the Philippines. Jpn J Infect Dis. 2014;67(2):105–10.

52. Imamura T, Fuji N, Suzuki A, et al. Enterovirus 68 among children with severe acute respiratory infection, the Philippines. Emerg Infect Dis. 2011;17(8):1430–5.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.